In Conversation

In Conversation: Helen Phillips of Gamida Cell on Advancing Cord Blood-Based Cell Therapies


For patients and physicians, particularly when time to transplant is critical, knowing that a donor source has been identified and is readily available is a significant benefit.

Gamida Cell defines its mission as pioneering the transformation of cells into powerful therapeutics. Founded more than 20 years ago, the biopharmaceutical company focuses on developing cord blood-derived and cell-based therapies for patients undergoing transplantation. In this month’s "In Conversation" interview, Helen Phillips, chief medical affairs officer at Gamida Cell, spoke with AABB News about the company’s commitment to bringing potentially curative cell therapies to patients and the evolving role of cord blood in hematology and cell therapy for hematologic malignancies and immune disorders.

Log in to read the full article.

This article is reserved for AABB members.
Please log in or join AABB to continue reading.

In Conversation

February 2026

February 2026 View Issue


Find More News

transfusion journal

Transfusion Journal

Transfusion is AABB’s scholarly, peer-reviewed monthly journal, publishing the latest on technological advances, clinical research and controversial issues related to transfusion medicine, blood banking, biotherapies and tissue transplantation. Access of Transfusion is free to all AABB members.

Learn More About Transfusion Journal
CellSource

AN UPDATE ON THE LATEST BIOTHERAPIES NEWS

Keep abreast of what's happening in the field of biotherapies with CellSource - AABB's monthly update on the latest biotherapies news.

Read and Subscribe Today

CONTACT US

To submit news about the blood and biotherapies field to AABB, please email news@aabb.org.

CONNECT WITH US

AABB News

President

Meghan Delaney, DO, MPH

Chief Executive Officer

Debra Ben Avram, FASAE, CAE

Chief Communications and Engagement Officer

Julia Zimmerman

Director of Marketing and Communications

Jay Lewis, MPH

Managing Editor

Kendra Y. Mims, MFA

Senior Communications Manager

Drew Case

AABB News

(ISSN 1523939X) is published monthly, except for the combined November/December issue for the members of AABB; 4550 Montgomery Avenue; Suite 700 North Tower; Bethesda, MD 20814.

AABB is an international, not-for-profit association representing individuals and institutions involved in transfusion medicine, cellular therapies and patient blood management. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.

+1.301.907.6977
Email: news@aabb.org
Website: www.aabb.org
Copyright 2025 by AABB.
Views and opinions expressed in AABB News are not necessarily endorsed by AABB unless expressly stated.

Notice to Copiers: Reproduction in whole or part is strictly prohibited unless written permission has been granted by the publisher. AABB members need not obtain prior permission if proper credit is given.

2025 APEX Awards for Publication Excellence